Did You Know...
...that power steering was invented by independent inventor Francis W. Davis? As chief engineer in the 1920s of the truck division of the Pierce Arrow Motor Car Company, he saw how hard it was to steer heavy vehicles. So that he would be able to keep the profits from his future invention, Davis left his job, rented a small engineering shop in Waltham, Mass., and developed a hydraulic power steering system that led to power steering.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8163286 | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL... | 04/24/2012 |
| 8158126 | Stem cell fusion model of carcinogenesis Methods for modeling cancer cell migration, screening drugs for effects on tumor cell migration, and detecting the potential for tumor cell migration relating to the fusion of a bone marrow derived stem cell with a genetically altered cell (FIG. 1). Antibodie... | 04/17/2012 |
| 8153128 | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor Binding members, especially antibody molecules that bind the IL-6:IL-6Ra complex formed by IL-6 and IL-6Ra, and do not bind either IL-6 or IL-6Ra alone. The binding members may have greater specificity for inhibiting pathological effects of IL-6 rather than benefici... | 04/10/2012 |
| 8142782 | EGFR inhibitors promote axon regeneration Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron. | 03/27/2012 |
| 8128932 | Anti-VEGFR monoclonal antibody, method of making and uses thereof The subject invention is directed to a VEGFR2 (vascular endothelial growth factor receptor II) monoclonal antibody (mAb), and the amino acid sequence of the heavy chain and the light chain of the mAb. The invention is also directed to methods for making the VEGFR2 m... | 03/06/2012 |
| 8119135 | Antibodies which bind to epitopes of glycoprotein VI The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders. ... | 02/21/2012 |
| 8105595 | Methods of using neutralizing anti-TLR4/MD2 antibodies This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using t... | 01/31/2012 |
| 8105596 | Immunotherapy of B-cell malignancies using anti-CD22 antibodies B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating ... | 01/31/2012 |
| 8048420 | Monoclonal antibody The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abn... | 11/01/2011 |
| 8034344 | Anti-IL-6/IL-6R antibodies and methods of use thereof This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. ... | 10/11/2011 |
| 8029792 | TCR-independent activation of T cells A method for TCR-independent T cell activation which comprises the co-ligation of CD28 and CD81. ... | 10/04/2011 |
| 8012480 | Detection of proteins from circulating neoplastic cells The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the prote... | 09/06/2011 |
| 8003102 | Anti-CXCR4 antibodies The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogen... | 08/23/2011 |
| 7993642 | Anti-MPL antibodies Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic ... | 08/09/2011 |
| 7981420 | Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for ... | 07/19/2011 |
| 7939073 | Immunotherapy of B-cell malignancies using anti-CD22 antibodies B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating ... | 05/10/2011 |
| 7939074 | Combination of an anti-EP-CAM antibody with a chemotherapeutic agent A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M. ... | 05/10/2011 |
| 7919092 | Antibodies to notch receptors The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targetin... | 04/05/2011 |
| 7914788 | Monoclonal antibodies against orthopoxviruses The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and ... | 03/29/2011 |
| 7910103 | Immunotherapy of B-cell malignancies using anti-CD22 antibodies B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating ... | 03/22/2011 |
| 7906119 | Antibodies against protective antigen The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The inve... | 03/15/2011 |
| 7901682 | Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agen... | 03/08/2011 |
| 7892548 | 121P1F1: a tissue specific protein highly expressed in various cancers A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ova... | 02/22/2011 |
| 7883702 | Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin s... | 02/08/2011 |
| 7867495 | Anti-GM-CSF antibodies and uses therefor The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for ex... | 01/11/2011 |
| 7862816 | Polypeptide compounds for inhibiting angiogenesis and tumor growth In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-a... | 01/04/2011 |
| 7846440 | Antibodies against ErbB3 and uses thereof The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. In a particular embodiment, the antibodies are capable of binding to ErbB3 and inhibiting ligand mediated phosphorylation of the rec... | 12/07/2010 |
| 7837995 | Immunotherapy of B-cell malignancies using anti-CD22 antibodies B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating ... | 11/23/2010 |
| 7824678 | Antibodies against cancer antigen TMEFF2 and uses thereof Described herein are methods and compositions that can be used for diagnosis and treatment of cancer. ... | 11/02/2010 |
| 7815907 | Antibodies to insulin-like growth factor I receptor The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeri... | 10/19/2010 |
| 7807166 | Methods of promoting remyelination of central nervous system axons by administrating sHIgM22 Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction ... | 10/05/2010 |
| 7807165 | Antibodies directed against amyloid-beta peptide and methods using same Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and Aβ peptide associated diseases are described. Methods of using antibodies directed agains... | 10/05/2010 |
| 7794719 | Anti-amyloid β antibodies The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region... | 09/14/2010 |
| 7790164 | Fragments of antibodies to epidermal growth factor receptor and methods of their use Antibody Fab fragments specific for the EGF receptor are disclosed, as are compositions and kits comprising these Fab proteins. The Fab proteins may be conjugated to drugs or other therapeutic agents or to diagnostic agents. Also disclosed are methods for diagnosing... | 09/07/2010 |
| 7790163 | Antibodies that bind both IL-17A and IL-17F and methods of using the same The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies ... | 09/07/2010 |
| 7785593 | Antibody (11C7) anti nogo a and its pharmaceutical use This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant | 08/31/2010 |
| 7780964 | Immunoglobulins which bind NOGO The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ... | 08/24/2010 |
| 7731965 | Human ring specific BNP antibodies The present invention relates to antibodies that specifically bind to human BNP and immunoassays using said antibodies in the quantification of human BNP or a fragment of human BNP in a test sample. ... | 06/08/2010 |
| 7727527 | Anti-NGF antibodies for the therapeutic treatments The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a signific... | 06/01/2010 |
| 7722871 | Immunoglobulins devoid of light chains The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is obtainable from a camelid heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding an antigen and which... | 05/25/2010 |
